SIA Partners U.s., Inc.

Elkridge, MD Doing business as Latham Biopharm Group

UEI
M7H6L5MK9MN8
CAGE
4GD67
Primary NAICS
541690 Other Scientific and Technical Consulting Services
SAM.gov registration
Expired

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
Other NAICS codes in SAM.gov
Show all 15
SAM.gov registration date
Physical address
6810 Deerpath Rd #405, Elkridge, MD 21075, USA
Founded
1996
Employees
51-250
Estimated annual revenue
$10M-$50M
Industry
  1. Industrials
  2. Commercial & Professional Services
  3. Professional Services
  4. Consulting
SIC code
87 Engineering & Management Services
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract obligations by fiscal year

Fiscal year Obligated
FY2027 To date $0
FY2026 $0
FY2025 -$29,323
FY2024 $55,000

Contract vehicles

Contract awards

Award Agency Obligated Awarded
Medicinal chemist support services HT942524P0111 Defense Health Agency $25,677

Contract subawards

Prime contractor Prime award Amount Awarded
University Of Maryland, Baltimore MAJOR TASKS (PHASE 1) BASE CONCERT: Consortium for Optimized Integration of Bio-artificial Blood Components for Adaptive Resuscitation and Therapy. N660012394005 $32,651
University Of Maryland, Baltimore MAJOR TASKS (PHASE 1) BASE CONCERT: Consortium for Optimized Integration of Bio-artificial Blood Components for Adaptive Resuscitation and Therapy N660012394005 $44,605
University Of Maryland, Baltimore EXERCISE OPTION 1 (PHASE II) AND EXTEND OPTION TASK 8. CONCERT: Consortium for Optimized Integration of Bio-artificial Blood Components for Adaptive… N660012394005 $83,727
University Of Maryland, Baltimore MAJOR TASKS (PHASE 1) BASE / INCREMENTAL FUNDING TO CLIN 0001 CONCERT: Consortium for Optimized Integration of Bio-artificial Blood Components for Adaptive… N660012394005 $374,459

Similar vendors

About the company

SIA Partners U.s., Inc., doing business as Latham Biopharm Group, is a life science consulting firm registered in SAM.gov since 2006, specializing in providing advanced scientific and consulting services to federal agencies in the pharmaceutical and biotechnology sectors. The company focuses on supporting pharmaceutical and biotech development programs, with particular expertise in infectious disease therapeutics, preclinical services, and research support for government agencies like the National Institutes of Health and Department of Defense. As a for-profit corporate entity, Latham Biopharm Group offers sophisticated technical services that bridge scientific research and practical development across multiple domains of medical and pharmaceutical innovation.

Through federal contract awards, Latham Biopharm Group has demonstrated significant capabilities in medicinal chemistry and preclinical service development. The company has received contract awards from agencies like the Defense Health Agency and the National Institute of Allergy and Infectious Diseases, providing services such as medicinal chemist support for antiviral therapeutics development and preclinical services supporting biopharmaceutical therapeutics and diagnostics. Their contract work has included sub-contract roles with entities like Vitrivax, Inc. and Battelle Memorial Institute, performing tasks ranging from contract compliance and program management to medical writing for clinical trials. These contracts have not been set aside for specific business types and cover a range of technical and scientific support services.

Regarding federal grant awards, Latham Biopharm Group has primarily worked as a sub-grantee through Yale University, specifically supporting the HEALR project funded by DARPA. Their grant-related work involves providing continuous services that contribute to deliverables submitted to DARPA, with monthly summaries of services provided. These grant collaborations emphasize the company's ability to integrate technical expertise into broader research initiatives and support advanced technological development programs.

The company holds a significant Indefinite Delivery Contract (IDV) from the National Institutes of Health National Institute of Allergy and Infectious Diseases, valued at $30 million with a performance period from January 2023 through September 2030. This single-award IDV enables task orders across five critical areas: product development planning and evaluation, analytical assay development, process development, CGMP manufacture, and regulatory activities. The IDV supports the advancement of therapeutic and diagnostic candidates through preclinical development, with a focus on preparing submissions to the U.S. Food and Drug Administration and supporting the agency's mission of understanding, treating, and preventing infectious diseases.

Quick answers

Is SIA Partners U.s., Inc. registered in SAM.gov?

SIA Partners U.s., Inc.'s SAM.gov registration expired on May 8, 2026.

Which contract vehicles does SIA Partners U.s., Inc. hold?

SIA Partners U.s., Inc. holds a place on 1 federal contract vehicle: OASIS+ Unrestricted.

How much has SIA Partners U.s., Inc. received in federal contracts?

Federal contracts obligated $25,677 to SIA Partners U.s., Inc. in fiscal years 2023 through 2027.

What is SIA Partners U.s., Inc.'s most recent federal award?

SIA Partners U.s., Inc.'s most recent federal contract award is Medicinal chemist support services (HT942524P0111), from Defense Health Agency, on September 25, 2024.

On GovTribe

See SIA Partners U.s., Inc.'s full federal record

  • Federal contract awards
  • IDV awards
  • Contract vehicles
  • Subcontracting relationships
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors